Efficacy and safety of etanercept in psoriasis after switching from other treatments: An observational study

American Journal of Clinical Dermatology

Volumn 10, Issue 5, 2009, Pages 319-324

  Mazzotta, Annamaria ^a   Esposito, Maria ^a   Costanzo, Antonio ^a   Chimenti, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; FUMARIC ACID DERIVATIVE; INFLIXIMAB; METHOTREXATE; PSORALEN; RETINOID; RETINOID DERIVATIVE;

ADULT; AGED; ARTICLE; ASTHENIA; BIOLOGICAL THERAPY; CLINICAL STUDY; CONTROLLED STUDY; CYSTITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HERPES LABIALIS; HUMAN; INJECTION SITE REACTION; LARYNGITIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OTITIS; PAIN ASSESSMENT; PHARYNGITIS; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; SCORING SYSTEM; SKIN ABSCESS; STOMACH ULCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; URTICARIA; VASCULITIS; VISUAL ANALOG SCALE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; BIOLOGICAL THERAPY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 68949148678     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11310770-000000000-00000     Document Type: Article

References (15)

1. De Rie MA, Goedkoop AY, Bos JD. Overview of psoriasis. Dermatol Ther 2004; 17: 341-349
2. Terajima S, Higaji M, Higarashi Y, et al. An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis. Arch Dermatol Res 1998; 290: 246-252
3. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022
4. Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis. Br J Dermatol 2005; 153 (3): 486-497
5. Fredricksson T, Petersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244
6. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632
7. Papp KA, Tyring S, Lahfa M, et al. Etanercept Psoriasis Study Group: a global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304-1312
8. Costanzo A, Mazzotta A, Papoutsaki M, et al. Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol 2005; 152: 176-198
9. van Vollenhoven R, Harju A, Brannemark S, et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed has failed or vice versa: data from the STURE registry showing the switching tumor necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003; 62: 1195-1198
10. Brocq O, Plubel Y, Breuil V, et al. Etanercept-infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti-TNF alpha. Presse Med 2002; 31: 1836-1839
11. Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheu-matol2004;31: 1098-1102
12. Gomez-Reino JJ, Carmona L, BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006; 8: R29
13. Delaunay C, Farrenq V, Marini-Portugal A, et al. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheum 2005; 32: 2183-2184
14. Pitarch G, Sánchez-Carazo JL, Mahiques L, et al. Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology 2008; 216: 312-316
15. Haraoui B. Is there a rationale for switching from one anti-tumor necrosis factor agent to another? J Rheumatol 2004; 31: 1021-1022